The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...

Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Soleno Therapeutics ( ($SLNO) ) has issued an announcement. During August 18-19, 2025, Soleno Therapeutics‘ senior management participated in a ...

Scorpion Capital disclosed a short position in Soleno Therapeutics on Friday, citing issues with the drugmaker's recently approved treatment Vykat XR, sending its shares slumping 15% in premarket ...

If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics (SLNO) could be a great choice. It is one of the several stocks that passed through our ...

Analysts are estimating that Soleno Therapeutics will report an earnings per share (EPS) of $-0.53. The market awaits Soleno Therapeutics's announcement, with hopes high for news of surpassing ...

Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $100 and keeps a Buy rating on the shares. The firm says ...

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best performing mid cap stocks so far in 2025. On July 10, Soleno Therapeutics announced that the sales of its new Prader-Willi disease drug ...